Kornimate/medical-research-clean huggingface dataset:
efficacy and safety of testosterone therapy in improving sarcopenia in men with cirrhosis.

Conditions: Liver Cirrhosis

Summary: * study population- patient with cirrhosis with any aetiology with sarcopenia visiting ilbs opd/ipds who are willing to visit ilbs gymnasium twice weekly for first month. * study design- a prospective randomized controlled trial * study period- study will be conducted at ilbs from april 2019 to oct 2019 * sample size:as shown by eva roman et al - in cirhotics with sarcopenia exercise increases mean lean appendicular mass , by 0.38 kg (14 patients, p \< 0.03), and sinclair et al has shown testosterone (22 patients, p \<0.05)) to increase mean appendicular lean mass by +1.69 kg - for 10% increase in aplm * we need to enroll 40 patients in each arm, and considering a los to follow up approx.10% , will require minimum 44 patients in each arm * we will therefore enroll and randomize 100 patients with 50 in each arm. intervention - testosterone supplementation - intramuscular testosterone undecanoate 1000 mg (4 ml volume in oily base) will be injected into the upper, outer quadrant of the buttock at 0, 6, 12,16,20, 24 weeks according to manufacturer recommendations. monitoring and assessment - on every visit patient will be inquired or evaluated for side effects like local site pain or hematoma , hypertension, headache, allergic reactions, acne, nausea , mood swings, pedal edema , breast enlargement and others.


Eligibility criteria:
inclusion criteria: * men with cirrhosis of any etiology * sarcopenia * ctp 6-12 exclusion criteria: * hepatocellular carcinoma * other known malignancy, * ctp \> 12 * acute liver injury * prostate disease, * known hypersensitivity to testosterone therapy, * polycythaemia (haematocrit \>55%), * uncontrolled hypertension (\>160/90 mmhg despite treatment), * uncontrolled obstructive sleep apnoea, * severe renal dysfunction (estimated glomerular filtration rate \<30ml/min) * uncontrolled epilepsy, migraine, or significant cardiac insufficiency (new york heart association class iii or iv or lvef \< 45-50%. * ckd (chronic kidney disease) - egfr (glomerular filtration rate) \<60% * platelet count below 30,000 or taking warfarin * failure to give consent.
effect of erchonia laser on erectile dysfunction

Conditions: Erectile Dysfunction

Summary: this study is to see if applying low-level laser light can provide improvement in erectile dysfunction

the purpose of this pilot study is to determine the effectiveness of the erchonia® hls™, manufactured by erchonia corporation (the company), in providing improvement in erectile dysfunction.

Eligibility criteria:
inclusion criteria: * male between 40 and 80 years old * known or suspected vasculogenic ed based on clinical history * in an active sexual relationship with a minimum of 2 sexual attempts per month for at least one month prior to enrollment * suffering from ed for at least 6 months * testosterone level between 300 - 1000ng/dl within one month prior to enrollment * hgb a1c less than or equal to 8% within one month prior to enrollment * total iief-ef scores between 8-25 * ehs score greater than or equal to exclusion criteria: * ed due to radical prostatectomy, prior pelvic surgery, or radiation therapy to the pelvis within 12 months prior to enrollment * men with known neurogenic or psychogenic ed * anatomic malformations of the penis including peyronie's disease * testosterone greater than 300ng/dl or 1000ng/dl * hgb a1c greater than 8% * international normalized ratio greater than 2.5, and men on any blood thinners other than 81mg aspirin * active testicular or prostate cancer
performance of continuous glucose monitoring systems at altitude

Conditions: Diabetes Mellitus, Type 1

Summary: 10 healthy volunteers will undergo the controlled lowering of their blood glucose level at sea level and a simulated altitude of 8,000 feet, to test the hypothesis that continuous glucose monitoring system measurement of blood glucose is as accurate at altitude as at sea level.


Eligibility criteria:
inclusion criteria: * age 18 - 60 years. * no known medical conditions or concomitant medication. exclusion criteria: * pregnancy. * marine diving in preceding 24 hours. * unable to provide written informed consent.

Keywords: diabetes mellitus, type 1 continuous glucose monitoring system accuracy altitude
peanuts and glycemic control

Conditions: Type2 Diabetes; Cardiovascular Diseases

Summary: a two-period randomized crossover study will be conducted to determine the effect of peanuts on glycemic control, and elucidate the role of the microbiome in glucose regulation, in individuals with impaired fasting glucose.

a two-period randomized crossover trial will be conducted. participants will be randomized to receive each treatment for 6 weeks followed by a minimum 4-week wash-out period. during the peanut treatment, participants will consume one ounce per day (28 g) of peanuts as an evening snack. the control treatments will be an isocaloric higher carbohydrate snack consumed after the evening meal. markers of glycemic control, cardiovascular risk factors and gut health will be assessed at the beginning and the end of each treatment period.

Eligibility criteria:
inclusion criteria: * non-smoking * impaired fasting glucose at screening (≥ 100 mg/dl). * bmi ≥20 and ≤40 kg/m2. exclusion criteria: * diagnosed diabetes or fasting glucose \>126 mg/dl * systolic blood pressure \>160mmhg or diastolic blood pressure \>100mmhg) * prescribed anti-hypertensive, lipid lowering or glucose lowering drugs * established cardiovascular disease, stroke, diabetes, liver, kidney or autoimmune disease or inflammatory conditions * use of supplements (psyllium, fish oil, soy lecithin, phytoestrogens) and botanicals and not willing to cease for the duration of the study * pregnancy or lactation * weight loss of \>=10% of body weight within the 6 months prior to enrolling in the study * smoking or use of any tobacco products * allergy to test foods * consumption of \>14 alcoholic drinks/week
comparison of hernia sac ligation versus invagination

Conditions: Hernia, Inguinal; Postoperative Pain; Recurrence

Summary: management of indirect hernial sac in inguinal hernia repairs has long been a subject of debate among general surgeons. although hernial sac high ligation (hl) is a time-honored concept in groin hernia surgery, non-ligation/invagination is gaining more popularity. the aim of this study is to compare the effects of hernia sac ligation and invagination in patients with lichtenstein mesh hernioplasty (lmh). also, investigators aimed to investigate the possible association between the hernial defect size and postoperative early pain in both groups.


Eligibility criteria:
inclusion criteria: * unilateral uncomplicated indirect hernia * elective operations * spinal anesthesia exclusion criteria: * bilateral hernias * recurrent cases * femoral-scrotal hernias * those who refused to give consent * those who were given general anesthesia besides spinal anesthesia * those who were repaired with a method other than lichtenstein mesh hernioplasty

Keywords: indirect hernia sac ligation invagination
osteolysis development around uncemented cups with or without screw holes

Conditions: Arthroplasty Complications

Summary: in order to investigate the role of acetabular cup screw holes for the transport of osteolysis-inducing particles in a total hip arthroplasty articulation, the investigators compare the amount of bone loss around acetabular cups with and without holes. bone loss is measured with computed tomography at 7 years and 15 - 18 years of follow-up.

particles generated by wear and corrosion within an artificial hip articulation can cause biologically mediated bone loss in the surrounding pelvis. particles can be found within immunologically active cells inside bone lesions. holes intended for screw fixation in uncemented acetabular cups are believed to be a main route for these particles from the articulation into the pelvic bone. using pressfit, screws are not always necessary for a successful fixation of an uncemented cup. the investigator's hypothesis is that a pressfit fixated cup without screw holes will display a decreased amount of periacetabular osteolysis compared to a cup with screw holes. therefore, 95 hips (90 patients) were randomized to receive either pressfit cups without screw holes or the same type of cup with screw holes. the occurence and size of periacetabular osteolysis will be compared between the two groups. in addition, since the patients will have a computed tomography examination at 7 years and between 15 and 18 years the investigator will also analyze development of periacetabular osteolysis over time. the different cups were paired with three different types of femoral stems. also, articulation wear and cup and stem fixation will be analyzed using radiostereometry.

Eligibility criteria:
inclusion criteria: * primary or secondary osteoarthritis exclusion criteria: * inflammatory osteoarthritis, hip joint infection

Keywords: uncemented hip arthroplasty osteolysis polyethylene wear implant design
study to assess the efficacy and safety of emapalumab in primary haemophagocytic lymphohistiocytosis

Conditions: Primary Hemophagocytic Lymphohistiocytosis

Summary: the purpose of this study is to expand the knowledge on the efficacy and safety of emapalumab (previously known as ni-0501) as a treatment for primary haemophagocytic lymphohistiocytosis (hlh) patients, including on long-term outcomes and quality of life assessments. emapalumab can be administered as the first-line therapy to patients not previously treated with the current standard of care, or can be given to patients who have either failed or were unable to tolerate the available standard of care. emapalumab is to be administered until the start of conditioning for hematopoietic stem cell transplantation (hsct), with an anticipated duration ranging from a minimum of 4 weeks to approximately 12 weeks and not exceeding 6 months. after treatment completion, patients will continue in the study for long-term follow-up until 1 year after either hsct or last emapalumab infusion (if hsct is not performed).


Eligibility criteria:
main inclusion criteria: * primary hlh patients with active disease. * treatment naïve patients or patients having already received hlh conventional therapy, but having not responded, not achieved a satisfactory response or worsened, or reactivated, or are unable to tolerate current standard of care. * informed consent signed by the patient or by the patient's legally authorized representative. * received guidance on contraception. main exclusion criteria: * diagnosis of secondary hlh consequent to a proven rheumatic, metabolic or neoplastic disease. * active mycobacteria, histoplasma capsulatum, shigella, salmonella, campylobacter or leishmania infections. * evidence of latent tuberculosis. * presence of malignancy. * concomitant disease or malformation severely affecting cardiovascular, pulmonary, central nervous system (cns), liver, or renal function, that in the opinion of the investigator may significantly affect the likelihood to respond to treatment and/or the assessment of emapalumab safety and/or efficacy. * history of hypersensitivity or allergy to any component of the study regimen. * receipt of a bcg vaccine within 12 weeks prior to screening. * receipt of a live or attenuated-live (other than bcg) vaccine within 6 weeks prior to screening. * pregnant or lactating female patients.

Keywords: interferon-gamma ni-0501 primary hlh emapalumab
clinical and biomolecular assessment for the monitoring of patients undergoing regenerative medicine treatments with orthobiologics

Conditions: Musculoskeletal System Disease

Summary: the aim is to improve the evaluation of the outcomes of regenerative medicine treatments performed in the regenerative medicine centers involved in the study. patients who undergo regenerative medicine treatments present acute and chronic pathologies of the musculoskeletal system, of the stomatological system and of the integuments. objective pre, peri and post treatment evaluations are collected. a dedicated software collects the proms compiled by the patients, the objective clinical data and the biomolecular evaluations.


Eligibility criteria:
inclusion criteria: * patients who received indication for regerative medicine treatment for one of the following pathologies: knee or hip or ankle osteoarthritis, patellar or achilles tendon pain, shouder or elbow pain; * males and females; * age \>= 6 years. exclusion criteria: * age \< 6 years * patients not compliant with post-treatment monitoring procedures * pregnancy
effect of xiaoer jiebiao oral liquid on hand-foot-mouth disease

Conditions: Handfoot-mouth Disease

Summary: this is a single-blinded randomized trial aiming to evaluate the effectiveness of xiaoer jiebiao oral liquid in combination with ribavirin treatment on patients with hand-foot-mouth disease compared with the controlgroup that recieve only libavirin treatment.


Eligibility criteria:
inclusion criteria:subjects should meet all of the following * diagnosed as hand-foot-mouth disease grade i or grade ii; * body temperature at admission t\>38℃，fever length\<48 hours; * no need for hormonotherapy or immunoglobulin therapy. * signed written informed consent form exclusion criteria:subjects should be excluded if meet any of the following * with history of any heart, lung, kidney or liver diseases; under any hormonotherapy, immunoglobulin therapy or any other therapy.

Keywords: mild and moderate severe patients with hand_foot-mouth disease
eus for gastrointestinal disorders: a registry

Conditions: GI Tract Disorders; Pancreatic Disorders; EUS

Summary: the aim of the eus registry is to record information about endoscopic ultrasound (eus) on the management of gastrointestinal disease. the registry will evaluate efficacy, safety and technical success of the endoscopic ultrasound (eus). design is retrospective and prospective registry study.


Eligibility criteria:
inclusion criteria: * all patients submitted to eus, * informed consent. exclusion criteria: * age less than 18 y * patient who did not give the consent to the processing of personal data.

Keywords: eus
cognitive remediation for autistic adolescents

Conditions: Autism Spectrum Disorder

Summary: autistic youth have extremely high levels of co-occurring mental health difficulties, including rates of depression and anxiety which are between two and four times more common compered to non-autistic people. cognitive inflexibility is a characteristic which is strongly associated with higher levels of anxiety and depression in autism. currently, there are no existing treatments which can promote flexible thinking. cognitive remediation therapy is a promising intervention which has been used with different patient groups to improve flexibility. this study aims to develop and adapt the current crt treatment for use with autistic youth and then conduct a pilot study with 20 participants.

the existing evidence that crt is effective for those with autistic features leads us to hypothesize that with minor adaptations the intervention will be acceptable to those with autism. given the strong association between ci and anxiety (and other internalizing difficulties such as depression; ref) by targeting this specific trait it is hypothesized that an adapted crt will a) increase flexible thinking and b) reduce symptoms of anxiety and depression. key objectives: 1. to use the existing literature of adapted interventions for autism and input from autistic youth and their parents to adapt crt for use with autistic youth. 2. to establish the acceptability of adapted crt by conducting a proof-of-principle pilot study. 3. to gather preliminary outcome data on ci, anxiety and depression, and other key measures such as levels of functional outcomes to inform the design of an acceptability and feasibility rct for future funding applications. methods: participants will all complete 8 adapted crt intervention sessions held twice weekly. outcome measures will be collected pre- and post intervention. measures of acceptability of the intervention (e.g., retention rate) will be recorded and qualitative interviews will gather feedback on the intervention.

Eligibility criteria:
inclusion criteria: * 12-16 years of age with a confirmed clinical diagnosis of autism (based on verified diagnostic report). * verbal/intellectual ability in average range * sufficient spoken english to access the intervention. * young person must be under the care of a local mental health service who can respond to any changes in routine clinical care / risk issues that arise. exclusion criteria: * not currently receiving alternative psychological intervention * not actively self-harming or deemed at risk to themselves or others
gallbladder cryoablation in high-risk patients

Conditions: Gallbladder Diseases; Cholecystitis; Biliary Colic; Gallstone; Cholecystitis; Biliary Dyskinesia; Gallstone; Gall Bladder Pain

Summary: benign gallbladder disease, including acute cholecystitis, chronic cholecystitis, biliary dyskinesia, and biliary colic, is very common, with over 300,000 surgical cholecystectomies performed per year in the us. unfortunately, complication rates in elderly patients or patients with many comorbidities are high. these patients are often managed with percutaneous tube drainage of the gallbladder (percutaneous cholecystostomy). the recurrence rate of calculous cholecystitis after cholecystostomy tube removal is as high as 35% at 1 year. these patients are thus faced with permanent cholecystostomy tube drainage, high-risk surgery, or cholecystostomy tube removal and risk of repeat cholecystitis. gallbladder cryoablation is an alternative to surgical cholecystectomy which is performed percutaneously and does not require general anesthesia. published evidence on the outcomes of gallbladder cryoablation is however limited at this point in time. the purpose of the proposed study is to follow the outcomes of high-risk patients who undergo gallbladder cryoablation.

the purpose of the proposed research is to evaluate the outcomes of gallbladder cryoablation in high-risk surgical candidates with benign gallbladder disease (acute cholecystitis, chronic cholecystitis, biliary dyskinesia, biliary colic). specific aim: aim 1: to evaluate the safety and efficacy of gallbladder cryoablation in high-risk surgical candidates. patients who undergo gallbladder cryoablation will be followed long-term according to standard of care. this includes scheduled clinic follow up, laboratory analysis, and imaging as needed. we hypothesize that gallbladder cryoablation is a safe and effective treatment for high-risk surgical patients with benign gallbladder disease. clinically, we hypothesize that patients will be free from any clinical symptoms or signs after gallbladder cryoablation and removal of a cholecystostomy tube. these include, but are not limited to right upper quadrant pain, fever, chills, and jaundice. aim 2: to evaluate the imaging changes seen in the gallbladder after cryoablation. imaging is part of routine follow up after percutaneous ablation and may include ct, mri, and nuclear medicine studies as needed. we hypothesize that after cryoablation, patients will be functionally acholecystic, which occlusion of the cystic duct and involution and fibrosis of the gallbladder demonstrated by imaging.

Eligibility criteria:
inclusion criteria: * high-risk surgical candidates with benign gallbladder disease who are not eligible for surgical cholecystectomy and are able to consent to study inclusion. exclusion criteria: * patients with benign gallbladder disease who are eligible for surgical cholecystectomy or who are unable to provide informed consent.

Keywords: cryoablation gallstones gallbladder cholecystitis
effect of different foot orthosis inverted angles on walking kinematics in females with flexible flatfeet

Conditions: Flexible Flatfoot

Summary: inverted orthosis is a type of rigid foot orthosis that was designed to aid in controlling high degrees of foot pronation. it is essential to administer patients foot orthoses with different inverted angles, with higher angles prescribed when greater reduction of foot pronation is indicated. however, there is shortage of clinical knowledge regarding the inverted angle in terms of biomechanical changes. the aim of this study is to investigate the effect of different inverted angles of foot orthoses on the walking kinematics in females with flexible flatfeet.


Eligibility criteria:
inclusion criteria: * females * within the age group of 18-35 years * asymptomatic flexible flatfeet * resting calcaneal stance position angle of ≥ 4° in valgus in both feet (bilateral) exclusion criteria: * previous surgery of the lower limbs or spine that might affect the performance of the study procedures * any severe medical or musculoskeletal conditions that may have affected the lower limbs * fixed flatfoot deformity * leg length discrepancy (\> 1cm) * pregnancy
renalase(rs10887800) genotyping & leucocytes telomere length in postpartum. hypertension

Conditions: Renalase(rs10887800) Genotyping & Leucocytes Telomere Length in Patients With Postpartum Hypertension

Summary: this is an observertional study aimed at study the association between renalase(rs10887800) genotyping \& leucocytes telomere length in patients with postpartum hypertension whether new onset( denovo) or persistent following pregnancy complicated by hypertension.


Eligibility criteria:
inclusion criteria: * patients who are18 years or above, and have a diagnosis of postpartum hypertension(regardless of where they received their antenatal care) attended to sohag university hospitals exclusion criteria: * all pregnant women with medical disorders in pregnancy other than hypertensive disorders during pregnancy (e.g., sickle cell disease, heart disease, kidney and other connective tissues disorders) will be excluded from the study. also we excluded measurements taken during scheduled or unscheduled surgical encounters given potential for interaction with anesthetic agents